@article {ZadikoffP2.047作者={辛迪Zadikoff和詹姆斯·博伊德和斯蒂芬妮Dubow Lars伯格曼和威宁Robieson Horia Ijacu和珍妮特Benesh}, title ={安全Levodopa-Carbidopa肠凝胶治疗晚期帕金森{\ textquoteright}年代疾病患者接受> = 2000毫克每日剂量左旋多巴(P2.047)},体积={90}={15}补充数量,elocation-id = {P2.047} ={2018},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:检查的安全Levodopa-Carbidopa肠凝胶治疗(LCIG carbidopa-levodopa肠内悬挂在美国)在晚期帕金森{\ textquoteright}年代疾病(PD)病人> = 2000毫克/天的剂量左旋多巴在临床研究期间。首页背景:LCIG是先进的PD患者的治疗选择电动机严重波动尽管优化药物治疗。发表剂量左旋多巴安全的数据是有限的,特别是对于> = 2000毫克。设计/方法:不良事件(AEs)病人在三期项目接受非盲LCIG综述了通过10月1日,2016年。患者事后归因分为2个剂量组\ < 2000毫克(N = 340), > = 2000毫克(N = 72)的意思是每天总左旋多巴。设备/过程AEs被排除在分析之外。现实世界安全数据格洛里亚的观察性研究也summarizedResults:大约17 \ %(72/412)先进的PD患者所需的三期项目> = 2000毫克/天的左旋多巴症状控制。现实世界的数据格洛丽亚观察研究反映了相似比例的患者接受> = 2000毫克每天(100毫升LCIG)左旋多巴(47/356 [13 \ %])。意思是基线(提单)病人剂量组之间是相似的特征。意味着(SD)提单口服左旋多巴剂量高> = 2000毫克/天组患者接受\ < 2000毫克/天(\ < 2000 mg: 1000.3[499.6]毫克;(693.3)> = 2000毫克:1464.8毫克)。 AEs were reported by 93\% of patients in the \<2000 mg/day group and 97\% of patients in the >=2000 mg/day group. AEs reported in >=15\% of patients in the >=2000 mg dose group with incidence rates >= twice that of the \<2000 mg dose group included PD (return/worsening of PD symptoms) (\<2000 mg: 14\%, >=2000 mg: 31\%) and vomiting (\<2000 mg: 9\%, >=2000 mg: 22\%). Serious AEs were reported by 44\% of patients in the \<2000 mg/day group and 64\% of patients receiving >=2000 mg/day.Conclusions: Patients that required >=2000 mg/day had higher BL oral levodopa doses and higher rates for some AEs compared to patients who received \<2000 mg/day levodopa. However, baseline characteristics and discontinuation due to AE were relatively similar between groups.Study Supported by: AbbVie Inc.Disclosure: Dr. Zadikoff has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, USworldMeds, Acadia, UCB, St Jude, Merz, Teva, Lundbeck. Dr. Boyd has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc., Teva, Lundbeck, Chrono Therapeutics, Neurocrine and Medical Education Resources. Dr. Boyd has received research support from Michael J. Fox Foundation, NIH/NINDS, Auspex, Biotie, CHDI Foundation, NeuroDerm, Chrono Therapeutics, Vaccinex, AbbVie Inc. Dr. Dubow has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc. Dr. Dubow holds stock and/or stock options in AbbVie Inc. Dr. Bergmann has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc. Dr. Bergmann holds stock and/or stock options in AbbVie Inc. Dr. Robieson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc. Dr. Robieson has received research support from AbbVie Inc. Dr. Ijacu has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc. Dr. Ijacu holds stock and/or stock options in AbbVie Inc. Dr. Benesh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc. Dr. Benesh holds stock and/or stock options in AbbVie Inc.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/90/15_Supplement/P2.047}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }